543 related articles for article (PubMed ID: 29803118)
21. Notch signaling pathway and Cdx2 expression in the development of Barrett's esophagus.
Tamagawa Y; Ishimura N; Uno G; Yuki T; Kazumori H; Ishihara S; Amano Y; Kinoshita Y
Lab Invest; 2012 Jun; 92(6):896-909. PubMed ID: 22449796
[TBL] [Abstract][Full Text] [Related]
22. [Cytokeratin immunoreactivity patterns in the diagnosis of Barrett's esophagus].
Wang R; Xie J; Shen Y; Ren T
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Dec; 32(12):1820-3. PubMed ID: 23268419
[TBL] [Abstract][Full Text] [Related]
23. c-Myc overexpression is strongly associated with metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
Schmidt MK; Meurer L; Volkweis BS; Edelweiss MI; Schirmer CC; Kruel CD; Gurski RR
Dis Esophagus; 2007; 20(3):212-6. PubMed ID: 17509117
[TBL] [Abstract][Full Text] [Related]
24. A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.
Ahmad J; Arthur K; Maxwell P; Kennedy A; Johnston BT; Murray L; McManus DT
Dis Esophagus; 2015 Apr; 28(3):276-82. PubMed ID: 24612412
[TBL] [Abstract][Full Text] [Related]
25. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
26. Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma.
Segat D; Cassaro M; Dazzo E; Cavallini L; Romualdi C; Salvador R; Vitale MP; Vitiello L; Fassan M; Rugge M; Zaninotto G; Ancona E; Baroni MD
Histol Histopathol; 2010 May; 25(5):551-60. PubMed ID: 20238294
[TBL] [Abstract][Full Text] [Related]
27. [Histochemical diagnosis of short segment Barrett's esophagus].
Fujiyama Y; Ishizuka I; Koyama S
Nihon Rinsho; 2005 Aug; 63(8):1420-6. PubMed ID: 16101233
[TBL] [Abstract][Full Text] [Related]
28. CDX2, COX2 and MUC2 expressions in Barrett's esophagus: can they be useful in determination of the dysplasia?
Türkmen IÇ; Başsüllü N; Uraz S; Yerdel MA; Memışoğlu R; Bülbül Doğusoy G
Turk Patoloji Derg; 2012; 28(3):251-8. PubMed ID: 23011828
[TBL] [Abstract][Full Text] [Related]
29. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
Inge LJ; Fowler AJ; Paquette KM; Richer AL; Tran N; Bremner RM
J Thorac Cardiovasc Surg; 2013 Feb; 145(2):531-8. PubMed ID: 23142123
[TBL] [Abstract][Full Text] [Related]
30. Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
Griffiths EA; Pritchard SA; McGrath SM; Valentine HR; Price PM; Welch IM; West CM
Br J Cancer; 2007 May; 96(9):1377-83. PubMed ID: 17437013
[TBL] [Abstract][Full Text] [Related]
31. Origins of Metaplasia in Barrett's Esophagus: Is this an Esophageal Stem or Progenitor Cell Disease?
Zhang W; Wang DH
Dig Dis Sci; 2018 Aug; 63(8):2005-2012. PubMed ID: 29675663
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic differences between esophageal and gastric intestinal metaplasia.
Piazuelo MB; Haque S; Delgado A; Du JX; Rodriguez F; Correa P
Mod Pathol; 2004 Jan; 17(1):62-74. PubMed ID: 14631367
[TBL] [Abstract][Full Text] [Related]
33. Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction.
Jovanovic I; Tzardi M; Mouzas IA; Micev M; Pesko P; Milosavljevic T; Zois M; Sganzos M; Delides G; Kanavaros P
Histol Histopathol; 2002 Apr; 17(2):445-54. PubMed ID: 11962749
[TBL] [Abstract][Full Text] [Related]
34. Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach.
Flucke U; Steinborn E; Dries V; Mönig SP; Schneider PM; Thiele J; Hölscher AH; Dienes HP; Baldus SE
Histopathology; 2003 Aug; 43(2):127-34. PubMed ID: 12877727
[TBL] [Abstract][Full Text] [Related]
35. Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies.
Lewis CJ; Thrumurthy SG; Pritchard S; Armstrong G; Attwood SE
Surg Endosc; 2011 Aug; 25(8):2564-9. PubMed ID: 21359892
[TBL] [Abstract][Full Text] [Related]
36. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma.
Huhta H; Helminen O; Lehenkari PP; Saarnio J; Karttunen TJ; Kauppila JH
Oncotarget; 2016 Apr; 7(17):23658-67. PubMed ID: 27008696
[TBL] [Abstract][Full Text] [Related]
37. MUC2 expression is an adverse prognostic factor in superficial gastroesophageal adenocarcinomas.
Davison JM; Ellis ST; Foxwell TJ; Luketich JD; Gibson MK; Kuan SF; Nason KS
Hum Pathol; 2014 Mar; 45(3):540-8. PubMed ID: 24290360
[TBL] [Abstract][Full Text] [Related]
38. Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.
Makita K; Kitazawa R; Semba S; Fujiishi K; Nakagawa M; Haraguchi R; Kitazawa S
World J Gastroenterol; 2013 Jan; 19(4):536-41. PubMed ID: 23382633
[TBL] [Abstract][Full Text] [Related]
39. Toll-like Receptor 2 Signalling and the Lysosomal Machinery in Barrett's Esophagus.
Verbeek RE; Siersema PD; Vleggaar FP; Ten Kate FJ; Posthuma G; Souza RF; de Haan J; van Baal JW
J Gastrointestin Liver Dis; 2016 Sep; 25(3):273-82. PubMed ID: 27689189
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical analysis of metaplastic non-goblet columnar lined oesophagus shows phenotypic similarities to Barrett's oesophagus: a study in an Asian population.
Srivastava S; Liew MS; McKeon F; Xian W; Yeoh KG; Ho KY; Teh M
Dig Liver Dis; 2014 Feb; 46(2):170-5. PubMed ID: 24290871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
